CRL
NEUTRALEarningsCharles River Laboratories Inte
This is the 2026-08-28 snapshot — the signals and analysis for CRL as of this single trading day.
View full CRL research hub →Analysis
Charles River Laboratories (CRL) is exhibiting High-Conviction Price Discovery, driven by a recent Q2 earnings beat and raised full-year guidance. The stock's +25.4% monthly surge has triggered PERFECT_STACK and MARKET_LEADER signals, showcasing dominant relative strength (+21.7% vs SPY). While recent insider selling and a minor Q3 estimate trim have caused a slight 1-day pullback, the low-volume consolidation (0.7x average) points to institutional absorption rather than distribution. Furthermore, the RISK_ON (RATES) macro regime—characterized by ultra-low credit spreads and a complacent VIX—provides a highly supportive backdrop for biotech R&D funding, reinforcing the structural bull case for CRL.
Fired Signals
Key Takeaways
- Bullish momentum is structurally underpinned by an August 5th Q2 earnings beat and raised guidance, triggering a GOLDEN_CROSS and MARKET_LEADER status.
- Recent insider selling by a company director and minor Q3 EPS estimate revisions are creating short-term friction, but low volume suggests a lack of institutional panic.
- The RISK_ON (RATES) macro regime heavily favors CRL, as zero liquidity stress and potential rate stability encourage biotech capital raises and outsourced R&D spending.